Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Dividends Paid - Preferred Dividends Paid - Preferred Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Lifecore Biomedical, Inc. \De\ (LFCR) Amortization of Deferred Charges (2023 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Amortization of Deferred Charges over the past 3 years, most recently at $18.8 million for Q2 2025.

For Q2 2025, Amortization of Deferred Charges rose 28.8% year-over-year to $18.8 million; the TTM value through May 2025 reached $20.2 million, up 31.12%, while the annual FY2025 figure was $20.2 million, 31.12% up from the prior year.
Amortization of Deferred Charges for Q2 2025 was $18.8 million at Lifecore Biomedical, Inc. \De\, up from -$7.4 million in the prior quarter.
Over five years, Amortization of Deferred Charges peaked at $18.8 million in Q2 2025 and troughed at -$7.4 million in Q1 2025.
A 3-year average of $4.5 million and a median of $3.6 million in 2023 define the central range for Amortization of Deferred Charges.
Biggest five-year swings in Amortization of Deferred Charges: skyrocketed 56.0% in 2024 and later tumbled 38.8% in 2025.
Year by year, Amortization of Deferred Charges stood at $3.1 million in 2023, then skyrocketed by 31.02% to $4.1 million in 2024, then skyrocketed by 359.92% to $18.8 million in 2025.
Business Quant data shows Amortization of Deferred Charges for LFCR at $18.8 million in Q2 2025, -$7.4 million in Q1 2025, and $4.1 million in Q4 2024.